Skip to content
Screener

Zevra Therapeutics, Inc. ZVRA Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)

Finite-Lived Intangible Assets - Expected Amortization Expense (Year One) at other companies

RFL
Rafael Holdings, Inc.RFL
$130K0.0%
Rigel Pharmaceuticals logo
Rigel PharmaceuticalsRIGL
$2.35M
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
$26.74M+13.4%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$2.9M

Other financials

Income statement

See full
Revenue$39.7M+53.3%
Gross profit$38.1M+182%
Operating income$16.8M+124%
Net income$8.8M-88.3%
EPS (diluted)$0.14-88.4%

Balance sheet

See full
Cash & equivalents$145.3M+205%
Total debt$1.5M-97.6%
Total equity$217.7M+85.7%
Total assets$302.7M+18.1%

Cash flow

See full
Operating cash flow$17.0M+573%
CapEx$217.0K+1.9%
Free cash flow$16.8M+541%

Valuation

See full
Market cap$686.48M+7.3%
Enterprise value$542.65M-17.1%
P/E11.8×-230×
P/S-5.3×

Profitability

See full
Gross margin95.5%+23.5pp
Operating margin-103.9%-43.0pp
Net margin42.8%+38.6pp
FCF margin-75%-30.5pp

Returns & leverage

See full
Return on equity34.8%+31.3pp
Debt / equity-0.5×
Current ratio5.2×-2.7×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour.

The source filing: Zevra Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001434647-26-000068
2026 (excluding the six months ended June 30, 2026)$632
20271,263
20281,263
2029632
2030

ITEM 1.FINANCIAL STATEMENTS

FAQ

What is Zevra Therapeutics, Inc.'s finite-lived intangible assets - expected amortization expense (year one)?
Zevra Therapeutics, Inc. (ZVRA) reported finite-lived intangible assets - expected amortization expense (year one) of $0 in Q2 2026.
What does finite-lived intangible assets - expected amortization expense (year one) mean?
This metric forecasts the amortization expense expected to be recognized in the upcoming fiscal year for intangible assets with finite useful lives. It provides visibility into the non-cash earnings impact of previously acquired intangible assets. Analysts use this to refine future earnings projections and cash flow models.

Ask your AI about Zevra Therapeutics, Inc.'s finite-lived intangible assets - expected amortization expense (year one).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude